Clinical Trials Directory

Trials / Completed

CompletedNCT03722940

Role of Magnesium in Pediatric Cochlear Implant

Combination of Magnesium Sulphate With Total Intravenous Anesthesia Optimized Surgical Field in Pediatric Cochlear Implant Surgery

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
66 (actual)
Sponsor
Wahba bakhet · Academic / Other
Sex
All
Age
Healthy volunteers
Accepted

Summary

To determine the efficiency of addition of magnesium sulfate to total intravenous anesthesia (TIVA) in optimizing the surgical field during pediatric cochlear implant surgery. Also its effects on the intraoperative evoked stapedial reflex thresholds (ESRT) and the intraoperative anesthetic requirements were evaluated.

Detailed description

Sixty-six ASA I and II children (1-6 years) undergoing cochlear implantation under general anesthesia were enrolled in this double blind, randomized study. Children were randomly allocated into two equal groups. Children in Group M (magnesium sulphate group) received an iv bolus dose of magnesium sulfate 40 mg Kg-1 over 5 minutes before induction of anesthesia followed by 15mg Kg-1 h-1 infusion until the start of skin closure. Children in Group C (Control group) received equivalent volumes of isotonic saline solution over the same period instead of magnesium sulphate. Haemodynamic variables, quality of surgical field, ESRT and the intraoperative anesthetic requirements were recorded

Conditions

Interventions

TypeNameDescription
DRUGMagnesium sulphateBefore induction of anesthesia; children in group M received an iv bolus dose of magnesium sulfate (Magnesium sulfate ampoule 1 gm/10 ml, Eipico, Egypt) 40 mg Kg-1 over 5 minutes followed by 15 mg Kg-1 h-1 ivi until the start of skin closure.
OTHERNa CL 0.9%Before induction of anesthesia; children in group C equivalent volumes of Na Cl 0.9% over the same period instead of magnesium sulphate.

Timeline

Start date
2014-06-01
Primary completion
2017-05-30
Completion
2018-08-01
First posted
2018-10-29
Last updated
2019-10-29

Source: ClinicalTrials.gov record NCT03722940. Inclusion in this directory is not an endorsement.